Cytokinetics (CYTK) Competitors

Genmab A/S (NASDAQ:GMAB) and Cytokinetics (NASDAQ:CYTK) are both medical companies, but which is the better investment? We will compare the two companies based on the strength of their institutional ownership, analyst recommendations, valuation, profitability, media sentiment, risk, dividends and earnings.

Does the media refer more to GMAB or CYTK?

In the previous week, Cytokinetics had 5 more articles in the media than Genmab A/S. MarketBeat recorded 15 mentions for Cytokinetics and 10 mentions for Genmab A/S. Genmab A/S's average media sentiment score of 0.70 beat Cytokinetics' score of 0.66 indicating that Genmab A/S is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Genmab A/S	4 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive
Cytokinetics	8 Very Positive mention(s)	1 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Which has higher valuation and earnings, GMAB or CYTK?

Genmab A/S has higher revenue and earnings than Cytokinetics. Cytokinetics is trading at a lower price-to-earnings ratio than Genmab A/S, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Genmab A/S	$3.26B	4.85	$1.14B	$1.99	12.39
Cytokinetics	$85.74M	53.51	-$589.53M	-$5.10	-7.52

Which has more volatility & risk, GMAB or CYTK?

Genmab A/S has a beta of 0.95, meaning that its share price is 5% less volatile than the S&P 500. Comparatively, Cytokinetics has a beta of 0.64, meaning that its share price is 36% less volatile than the S&P 500.

Is GMAB or CYTK more profitable?

Genmab A/S has a net margin of 37.53% compared to Cytokinetics' net margin of -707.17%. Genmab A/S's return on equity of 21.03% beat Cytokinetics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Genmab A/S	37.53%	21.03%	16.98%
Cytokinetics	-707.17%	N/A	-45.52%

Do analysts prefer GMAB or CYTK?

Genmab A/S presently has a consensus target price of $37.60, suggesting a potential upside of 52.54%. Cytokinetics has a consensus target price of $71.58, suggesting a potential upside of 86.71%. Given Cytokinetics' stronger consensus rating and higher probable upside, analysts clearly believe Cytokinetics is more favorable than Genmab A/S.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Genmab A/S	1 Sell rating(s)	3 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.64
Cytokinetics	0 Sell rating(s)	3 Hold rating(s)	10 Buy rating(s)	2 Strong Buy rating(s)	2.93

Do institutionals and insiders believe in GMAB or CYTK?

7.1% of Genmab A/S shares are held by institutional investors. 1.5% of Genmab A/S shares are held by insiders. Comparatively, 2.7% of Cytokinetics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Summary

Genmab A/S beats Cytokinetics on 10 of the 17 factors compared between the two stocks.